---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: STOP-HAE"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: STOP-HAE. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 51 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence/stop-hae"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: STOP-HAE

<a id="heading-3.1.1"></a>

## 3.1.1 STOP-HAE

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Registry brief summary

> “This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema.”
> “The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.1-2"></a>

#### Primary and secondary objectives

> “The primary objective of the Phase 3 study is to evaluate the efficacy of onvuzosiran in preventing HAE attacks in patients with HAE.”
> “The secondary objective is to characterize the effects of onvuzosiran on the quality and pattern of HAE attacks”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.1-3"></a>

#### UK ethics summary: study aim

> “This study will evaluate how effective ADX-324 is in preventing HAE attacks compared with a placebo (a similar looking 'drug' with no active medications) in participants with HAE.”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Registry dates and number of locations

> “Study Start (Actual) 2025-08-28 Primary Completion (Estimated) 2027-11-30 Study Completion (Estimated) 2027-12-31”
> “This study has 70 locations”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.2-2"></a>

#### Trial initiation, planned sites, and topline timing

> “In August 2025, we initiated our Phase 3 STOP-HAE clinical trial.”
> “Approximately 90 participants with Type I or Type II HAE will be enrolled in 70 global sites.”
> “STOP-HAE enrollment is ongoing, with topline data expected by the end of 2027.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.2-3"></a>

#### First participant dosed

> “today announced that the first patient has been dosed in its Phase 3 STOP-HAE clinical trial evaluating ADX-324 in patients with hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals (2025)](https://www.adarx.com/adarx-pharmaceuticals-announces-first-patient-dosed-in-phase-3-stop-hae-clinical-trial-and-orphan-drug-designation-for-adx-324-a-long-acting-sirna-in-development-for-the-prophylactic-treatment-of-her/)

<a id="topic-3.1.1.2-4"></a>

#### Sites and countries reported at EAACI 2026

> “at least 60 sites in 22 countries”
> “First patient dosed in Q4 2025.”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.1.2-5"></a>

#### UK research ethics committee opinion

| Field | Reported value |
| --- | --- |
| REC reference | “25/NE/0161” |
| Date of REC opinion | “16 Oct 2025” |
| REC opinion | “Further Information Favourable Opinion” |

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)

<a id="topic-3.1.1.2-6"></a>

#### French trial sites

> “Centre Hospitalier Universitaire Grenoble Alpes”
> “Centre Hospitalier Universitaire De Nice”
> “Centre Hospitalier Regional Universitaire De Tours”

Source: [Santé.fr (2026)](https://www.sante.fr/essais-cliniques/2025-521352-38-00/stop-hae-etude-de-phase-iii-randomisee-en-double-aveugle-et-controlee-par-placebo-evaluant-l-action-de-l-adx-324-un-sirna-ciblant-la-prekallikreine-chez-des-participants-atteints-d-angio-oedeme-hereditaire)

<a id="topic-3.1.1.2-7"></a>

#### Topline data timing at the Q3 2026 update

> “Onvuzosiran (PKK): Phase 3 STOP-HAE topline data by year-end 2027”

Source: [ADARx Pharmaceuticals third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Registry design details

| Field | Reported value |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Model description | “Randomized, double-blind, placebo-controlled study” |
| Masking | “Quadruple” |
| Masking description | “Double blinded” |

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.3-2"></a>

#### Washout, screening, and randomization

> “In this trial, participants undergo a washout of previous long term prophylaxis treatment and then enter a 4-week screening window where baseline HAE attack rate is measured, and then randomized to either 300mg Q6M, 240 mg Q3M or placebo.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.3-3"></a>

#### Randomization ratio, stratification, and visit schedule

> “Randomization (1:1:1)”
> “Stratified by monthly HAE attacks rate”
> “Screening period (up to 8 weeks)”
> “Screening, Day 1 (Dose 1), W3, W5, W9, W13 (Dose 2), W17, W21, W25 (EoS)”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.1.3-4"></a>

#### Post-dose visits and study duration

> “After the start of study drug administration, participants will return to the hospital for 7 post-dose visits at 2- or 4-week intervals for effectiveness and safety tests for 6 months.”
> “The study ends upon completion of the 6 month visits.”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)

<a id="topic-3.1.1.3-5"></a>

#### Participant timeline on the trial website

> “Screening – 4 to 8 weeks”
> “Study and follow-ups – 25 weeks”
> “The initial study, STOP-HAE, will take approximately 7-8 months to complete.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="topic-3.1.1.3-6"></a>

#### Transition to the long-term extension

> “A long-term extension clinical trial will further evaluate open-label onvuzosiran treatment for up to three years, with, after 6 months, all participants (including placebo patients from STOP-HAE) moved onto active drug in the open label long term follow up.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.3-7"></a>

#### Regulatory input on the phase 3 design

> “Positive feedback from FDA to move forward with Phase 3 STOP-HAE study.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Registry key inclusion criteria

> “Age ≥18 years at the time of signing informed consent.”
> “Have a documented diagnosis of HAE-1/HAE-2 (Type I or II)”
> “Experience ≥1 Investigator-confirmed HAE attack in the first 4 weeks of Screening or ≥2 Investigator-confirmed HAE attacks in 8 weeks of Screening”
> “Able to use at least one acute therapy to treat HAE attacks (such as a plasma-derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.4-2"></a>

#### Registry key exclusion criteria

> “Concurrent diagnosis of another form of recurrent angioedema (such as acquired angioedema, HAE with normal C1-INH (previously known as HAE Type III), idiopathic angioedema, or recurrent angioedema associated with urticaria).”
> “Any clinically significant renal disease”
> “Any clinically significant hepatic disease”
> “Received prior treatment with any RNA/DNA-based therapy for HAE or intolerant to any prior RNA/DNA-based therapy for any condition, excluding vaccines.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.4-3"></a>

#### Registry washout periods for long-term prophylaxis

> “C1-INH agent (CINRYZE, HAEGARDA, RUCONEST) within 2 weeks prior to Screening.”
> “Berotralstat (ORLADEYO) within 3 weeks prior to Screening.”
> “Lanadelumab (TAKHZYRO) within 8 weeks prior to the Screening.”
> “Androgen use within 12 weeks prior to Screening.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.4-4"></a>

#### EU record: laboratory criteria for the HAE diagnosis

> “Avoir un diagnostic documenté d’HAE-1 ou d’HAE-2 reposant sur l’ENSEMBLE des critères suivants (a, b ET c)”
> “Taux d’antigène C1-INH < 50 % de la limite inférieure de la normale (LIN).”
> “Niveau fonctionnel de C1-INH < 50 % de la LIN.”

Source: [Santé.fr (2026)](https://www.sante.fr/essais-cliniques/2025-521352-38-00/stop-hae-etude-de-phase-iii-randomisee-en-double-aveugle-et-controlee-par-placebo-evaluant-l-action-de-l-adx-324-un-sirna-ciblant-la-prekallikreine-chez-des-participants-atteints-d-angio-oedeme-hereditaire)

<a id="topic-3.1.1.4-5"></a>

#### EU record: suitability for on-demand treatment alone

> “Les participants doivent être jugés médicalement aptes à suivre un traitement à la demande comme seule prise en charge médicamenteuse.”

Source: [Santé.fr (2026)](https://www.sante.fr/essais-cliniques/2025-521352-38-00/stop-hae-etude-de-phase-iii-randomisee-en-double-aveugle-et-controlee-par-placebo-evaluant-l-action-de-l-adx-324-un-sirna-ciblant-la-prekallikreine-chez-des-participants-atteints-d-angio-oedeme-hereditaire)

<a id="topic-3.1.1.4-6"></a>

#### EU record: renal function, ACE inhibitors, estrogens, and prior RNA therapy

> “une insuffisance rénale sévère (IRC de stade 3, DFG estimé < 60 ml/min/1,73 m² ; antécédents de syndrome néphrotique)”
> “Inhibiteurs de l’ECA au cours des 4 semaines précédant le dépistage.”
> “Nouvelle prise ou augmentation de la dose de médicaments contenant des œstrogènes et à absorption systémique (tels que les contraceptifs oraux ou le traitement hormonal substitutif) au cours des 3 mois précédant le dépistage.”
> “A déjà reçu un traitement par une thérapie à base d’ARN ou d’ADN pour l’AOH (y compris l’ADX-324)”

Source: [Santé.fr (2026)](https://www.sante.fr/essais-cliniques/2025-521352-38-00/stop-hae-etude-de-phase-iii-randomisee-en-double-aveugle-et-controlee-par-placebo-evaluant-l-action-de-l-adx-324-un-sirna-ciblant-la-prekallikreine-chez-des-participants-atteints-d-angio-oedeme-hereditaire)

<a id="topic-3.1.1.4-7"></a>

#### Acute medication access and washout timing

> “Access to acute medication(s) for attacks provided for all study participants”
> “LTP washout must be completed before Screening, if applicable”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.1.4-8"></a>

#### Trial website criteria: prophylaxis discontinuation, medical history, and eDiary

> “Be willing to stop any long-term, preventative medication used to prevent attacks”
> “Have no significant medical history that could interfere with the study (for example, hypertension, diabetes or cardiovascular disease)”
> “Have a mobile phone to register and set up your eDiary account”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Registry interventions

| Intervention | Reported description |
| --- | --- |
| ADX-324 | “siRNA duplex oligonucleotide” |
| Placebo | “saline” |

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.5-2"></a>

#### Randomized treatment groups and injection volumes

| Treatment group | Reported value |
| --- | --- |
| Onvuzosiran every 6 months | “ADX-324 300 mg Q6M (1.5ml)” |
| Onvuzosiran every 3 months | “ADX-324 240 mg Q3M (1.2ml)” |
| Placebo, larger volume | “Placebo (1.5 ml) n=15” |
| Placebo, smaller volume | “Placebo (1.2 ml) n=15” |

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.1.5-3"></a>

#### Blinded dosing on Day 1 and Week 13

> “Participants will be randomly assigned to 1 of 3 treatment groups. 1) ADX-324 300mg on day 1 (D1) + Placebo on Week 13 (W13), 2) ADX-324 240mg D1 + ADX-324 240mg W13, 3) Placebo D1 + Placebo W13.”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)

<a id="topic-3.1.1.5-4"></a>

#### Dose selection relative to the phase 2a doses

> “Phase 3 dose cohorts: 300 mg Q6M or 240 mg Q3M”
> “The attack-free interval seen with these subtherapeutic doses supported our choice of doses in our ongoing STOP-HAE Phase 3 trial.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.5-5"></a>

#### Pharmacodynamic target for the 300 mg dose

> “supporting the Phase 3 target >80% PKK-KK reduction throughout 6 months in HAE patients at the 300 mg dose”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.1.5-6"></a>

#### Number of active doses during the controlled period

> “Depending on your dosing schedule, you may only have to receive one dose of the investigational drug in this period.”
> “You will not know which group you are assigned to.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="topic-3.1.1.5-7"></a>

#### On-demand treatment and home nursing visits

> “You will be able to take your on-demand, rescue medication if you experience an attack.”
> “While in the study, participants who choose to take part may be able to also opt-in to having home nursing visits if your trial doctor agrees.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoint: registry definition

> “The time-normalized number of Investigator-confirmed HAE attacks per month for ADX-324 Dose Level 1 vs placebo”
> “Day 22 to Week 25”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.6.1-2"></a>

##### Exclusion of attacks before Day 22

> “Per feedback from the FDA, HAE attacks before Day 22 will be excluded from primary endpoint analysis, consistent with the siRNA proposed mechanism of action.”
> “One known feature of siRNA therapeutic candidates such as onvuzosiran is lag time of about 22 days between initial treatment and full inhibition.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.6.1-3"></a>

##### Attack recording by daily eDiary

> “using a daily eDiary to report HAE attacks, should these occur”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="topic-3.1.1.6.1-4"></a>

##### Guideline treatment goal: absence of attacks

> “We recommend that the goals of treatment are to achieve total control of the disease and to normalize patients' lives.”
> “Complete control of their disease, for HAE patients, translates to no longer having attacks.”
> “These treatments significantly reduce attack rates, and many patients achieve complete response.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-3.1.1.6.1-5"></a>

##### Phase 2a relationship between prekallikrein suppression and attacks

> “We also correlated the episodes of attack with the PKK levels and found that no attacks occurred when the PKK suppression was >80%, suggesting that >80% suppression is potentially needed to achieve a maximal attack-free state.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.6.1-6"></a>

##### Sponsor target profile for attack outcomes

> “Our target profile for onvuzosiran is to reach greater than 90% reduction in monthly attacks, with greater than 75% of patients achieving attack-free status, on Q3M or Q6M dosing schedule.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.6.1-7"></a>

##### Secondary endpoints: registry definitions

> “The time-normalized number of Investigator-confirmed HAE attacks per month for ADX-324 Dose Level 2 vs placebo”
> “The time-normalized number of Investigator-confirmed HAE attacks requiring acute HAE therapy per month for ADX-324 vs placebo.”
> “The time-normalized number of moderate or severe Investigator confirmed HAE attacks per month for ADX 324 vs placebo.”
> “The proportion of participants who have not experienced an Investigator-confirmed HAE attack (HAE attack-free) for ADX 324 vs placebo.”
> “The proportion of participants with a clinical response defined as a ≥50%, ≥70%, or ≥90% reduction from baseline in Investigator-confirmed HAE attack rate for ADX 324 vs placebo.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.6.1-8"></a>

##### Patient-reported outcomes: AECT and AE-QoL

> “In addition, efficacy, PK activity, PD activity and patient-reported health-related quality of life (AECT and AE-QoL) will also be assessed.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.6.1-9"></a>

##### Exploratory endpoint instruments

> “AECT: Angioedema Control Test, AE-QoL: Angioedema Quality of Life”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.1.6.1-10"></a>

##### Validation of outcomes instruments: AECT scoring and cut-off

> “The AECT comes with high levels of internal consistency and test-retest-reliability and a cut-off value of 10 points to distinguish patients with poorly controlled and well controlled HAE.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-3.1.1.6.1-11"></a>

##### Validation of outcomes instruments: AECT development

> “A 4-item AECT with recall periods of 4 weeks and 3 months was developed based on 106 potential items tested in 97 patients with mast cell mediator-induced (n = 49) or bradykinin-mediated recurrent AE (n = 48).”
> “Its validity and reliability need to be determined in future independent studies.”

Source: [Weller et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31815297/)

<a id="topic-3.1.1.6.1-12"></a>

##### Validation of outcomes instruments: AE-QoL minimal clinically important difference

> “The MCID of the AE-QoL total score was found to be six points.”

Source: [Weller et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27038109/)

<a id="topic-3.1.1.6.1-13"></a>

##### Validation of outcomes instruments: AE-QoL content validation and psychometric evaluation

> “Patients agreed that the questionnaire items and response options were clear and relevant, and the 4-week recall period was appropriate.”

Source: [Vanya et al. (2023)](https://link.springer.com/article/10.1186/s41687-023-00576-w)

<a id="topic-3.1.1.6.1-14"></a>

##### Validation of outcomes instruments: AE-QoL content validation in adults and adolescents

> “Adolescents also reported that questions about school-related impacts were missing and would be important to ask about specifically.”

Source: [Broderick et al. (2025)](https://link.springer.com/article/10.1186/s41687-025-00876-3)

<a id="topic-3.1.1.6.1-15"></a>

##### Validation of outcomes instruments: AE-QoL psychometric validation

> “The AE-QoL demonstrated strong reliability, validity, and ability to detect change”

Source: [Feld et al. (2026)](https://link.springer.com/article/10.1186/s41687-026-01128-8)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Registry planned enrollment

> “Enrollment (Estimated) 90”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-3.1.1.7.1-2"></a>

##### Planned participants per treatment group

| Treatment group | Planned participants |
| --- | --- |
| “ADX-324 300 mg Q6M (1.5ml)” | “n=30” |
| “ADX-324 240 mg Q3M (1.2ml)” | “n=30” |
| Placebo | “Placebo (1.2 ml) n=15 or (1.5 ml) n=15” |

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.1.7.1-3"></a>

##### Participants analyzed

No evidence found.

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Primary comparison and superiority criterion

> “The analysis that will affirm this objective is the comparison of the time-normalized number of investigator-confirmed HAE attacks (per month) from Day 22 to Week 25 visit in patients dosed with onvuzosiran at 300 mg Q6M with those dosed with placebo (PBO).”
> “A statistically significant reduction in attack rate will demonstrate the statistical superiority of onvuzosiran.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.1.7.2-2"></a>

##### Analysis populations

No evidence found.

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

No results are available. The trial began in August 2025, enrollment is ongoing, and the estimated primary completion date is November 2027, with topline data expected by the end of 2027. Planned enrollment is approximately 90 participants: 30 per onvuzosiran group and 30 receiving placebo, divided into two injection volumes of 15 participants each. This sample size limits the precision of safety estimates and of any subgroup analysis. The primary endpoint compares only the 300 mg every-6-months group with placebo; the 240 mg every-3-months comparison is a secondary endpoint. The controlled period lasts 25 weeks, so participants in the every-6-months group receive one active dose and the controlled data do not cover a second 6-month dosing interval. Attacks before Day 22 are excluded from the primary analysis, so the primary endpoint does not describe protection during the first 3 weeks after the first dose. The comparator is placebo, so the trial does not provide a direct comparison with an approved long-term prophylactic agent. Eligibility is limited to adults with type I or type II HAE who have at least 1 investigator-confirmed attack in the first 4 weeks of screening or at least 2 in 8 weeks, who complete washout of long-term prophylaxis, and who are judged able to use on-demand treatment alone; HAE with normal C1 inhibitor, clinically significant renal or hepatic disease, and prior RNA- or DNA-based HAE therapy are excluded. The doses were selected from pharmacodynamic data in healthy volunteers and from the attack-free intervals of 3 participants with HAE whose phase 2a doses were lower or less frequent than the phase 3 regimens. The design is described only in the registry record, ethics summaries, and sponsor documents; no peer-reviewed protocol publication was identified.

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213); [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm); [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf); [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf); [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/); [Santé.fr (2026)](https://www.sante.fr/essais-cliniques/2025-521352-38-00/stop-hae-etude-de-phase-iii-randomisee-en-double-aveugle-et-controlee-par-placebo-evaluant-l-action-de-l-adx-324-un-sirna-ciblant-la-prekallikreine-chez-des-participants-atteints-d-angio-oedeme-hereditaire); [ADARx Pharmaceuticals](https://stophae.com/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
